PMC9700445_01
PMC9700445_02
Topical corticosteroid drops OU and previous intravitreal triamcinolone OS, widefield fluorescein angiography (Optos) and optical coherence tomography. Bright green line indicates section of image provided and green arrow has no significance.
IMCRJ-15-665-g0001.jpg
PMC9700445_02_IMCRJ-15-665-g0001.jpg
f0001
TX, USA) OS (Figure 1).
Persistent inflammation 6 weeks after Ozudex OD and 8 weeks after Ozurdex OS, widefield fluorescein angiography (Optos) and optical coherence tomography. Bright green line indicates section of image provided and green arrow has no significance.
IMCRJ-15-665-g0002.jpg
PMC9700445_02_IMCRJ-15-665-g0002.jpg
f0002
At just 6 weeks after Ozudex OD and 8 weeks after Ozurdex OS, follow-up revealed BCVA improved from 20/80 to 20/60 OD, but worsened from 20/70 to 20/200 OS (IOP was stable and within normal limits) (Figure 2).
Improved macular edema 3 months after YUTIQ OD and 1 month after YUTIQ OS, widefield fluorescein angiography (Optos) and optical coherence tomography. Bright green line indicates section of image provided and green arrow has no significance.
IMCRJ-15-665-g0003.jpg
PMC9700445_02_IMCRJ-15-665-g0003.jpg
f0003
Follow-up showed improvement in vision, macular edema, and macular leakage on fluorescein angiography imaging (Figure 3): at 3 months after YUTIQ OD and 1 month after YUTIQ OS, BCVA improved from 20/60 to 20/50 OD and 20/70 to 20/40 OS.